Review article · 2021 · Open access
Blood‐based biomarkers for Alzheimer's disease
EMBO Molecular Medicine, 14(1), e14408 · Published 3 December 2021 · DOI 10.15252/emmm.202114408
In brief
“Blood‐based biomarkers for Alzheimer's disease” is a 2021 review article by Antoine Leuzy and 5 co-authors, published in EMBO Molecular Medicine. OpenAlex counts 394 citations as of 19 November 2026, which puts it in the top 1% of works published in 2021 by citations. It is open access: the full text is free to read at EMBO Molecular Medicine.
- Citations
- 394
- Most cited in
- 2025 (105)
- Field-weighted impact
- 6.73
- References
- 158
- Authors
- 6
Abstract
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying pathophysiology are playing an ever-increasing role in research, clinical trials, and in the clinical work-up of patients. Though cerebrospinal fluid (CSF) and positron emission tomography (PET)-based measures are available, their use is not widespread due to limitations, including high costs and perceived invasiveness. As a result of rapid advances in the development of ultra-sensitive assays, the levels of pathological brain- and AD-related proteins can now be measured in blood, with recent work showing promising results. Plasma P-tau appears to be the best candidate marker during symptomatic AD (i.e., prodromal AD and AD dementia) and preclinical AD when combined with Aβ42/Aβ40. Though not AD-specific, blood NfL appears promising for the detection of neurodegeneration and could potentially be used to detect the effects of disease-modifying therapies. This review provides an overview of the progress achieved thus far using AD blood-based biomarkers, highlighting key areas of application and unmet challenges.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Leuzy, A., Mattsson, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2021). Blood‐based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 14(1), e14408. https://doi.org/10.15252/emmm.202114408
MLA 9
Leuzy, Antoine, et al. “Blood‐based biomarkers for Alzheimer's disease.” EMBO Molecular Medicine, vol. 14, no. 1, 2021, p. e14408. https://doi.org/10.15252/emmm.202114408.
Chicago
Leuzy, Antoine, Niklas Mattsson, Sebastian Palmqvist, Shorena Janelidze, Jeffrey L. Dage, and Oskar Hansson. 2021. “Blood‐based biomarkers for Alzheimer's disease.” EMBO Molecular Medicine 14 (1): e14408. https://doi.org/10.15252/emmm.202114408.
Harvard
Leuzy, A. et al. (2021) ‘Blood‐based biomarkers for Alzheimer's disease’, EMBO Molecular Medicine, 14(1), p. e14408. doi:10.15252/emmm.202114408.
IEEE
A. Leuzy, N. Mattsson, S. Palmqvist, S. Janelidze, J. L. Dage, and O. Hansson, “Blood‐based biomarkers for Alzheimer's disease,” EMBO Molecular Medicine, vol. 14, no. 1, p. e14408, 2021, doi: 10.15252/emmm.202114408.
BibTeX
@article{leuzy2021blood,
title = {{Blood‐based biomarkers for Alzheimer's disease}},
author = {Leuzy, Antoine and Mattsson, Niklas and Palmqvist, Sebastian and Janelidze, Shorena and Dage, Jeffrey L. and Hansson, Oskar},
journal = {EMBO Molecular Medicine},
year = {2021},
volume = {14},
number = {1},
pages = {e14408},
doi = {10.15252/emmm.202114408},
url = {https://doi.org/10.15252/emmm.202114408}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 29 | |
| 2023 | 77 | |
| 2024 | 91 | |
| 2025 | 105 | |
| 2026 | 91 |
Its field-weighted citation impact is 6.73: it has been cited 6.73 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Alzheimer's disease
- blood-based biomarkers
- amyloid-beta 42/40 ratio
- neurofilament light chain
- preclinical Alzheimer's disease
- prodromal Alzheimer's disease
- neurodegeneration
- disease-modifying therapy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Leuzy, A., Mattsson, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2021). Blood‐based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 14(1), e14408. https://doi.org/10.15252/emmm.202114408
How many times has this paper been cited?
394 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at EMBO Molecular Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Antoine Leuzy, Niklas Mattsson, Sebastian Palmqvist, Shorena Janelidze, Jeffrey L. Dage, Oskar Hansson.
What is the DOI of this paper?
10.15252/emmm.202114408, permanently at https://doi.org/10.15252/emmm.202114408. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.